Wall Street analysts expect Xencor Inc (NASDAQ:XNCR) to announce earnings of ($0.58) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Xencor’s earnings, with the highest EPS estimate coming in at ($0.53) and the lowest estimate coming in at ($0.63). Xencor posted earnings per share of $0.05 in the same quarter last year, which would indicate a negative year-over-year growth rate of 1,260%. The company is scheduled to issue its next earnings report on Monday, November 4th.
On average, analysts expect that Xencor will report full-year earnings of $0.08 per share for the current financial year, with EPS estimates ranging from ($0.13) to $0.23. For the next fiscal year, analysts anticipate that the company will post earnings of ($1.84) per share, with EPS estimates ranging from ($3.12) to ($0.99). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Xencor.
Xencor (NASDAQ:XNCR) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.15. The firm had revenue of $19.49 million during the quarter, compared to analysts’ expectations of $7.58 million. Xencor had a net margin of 28.46% and a return on equity of 8.40%.
In other news, insider John J. Kuch sold 40,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $41.27, for a total value of $1,650,800.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder John S. Stafford III bought 12,641 shares of Xencor stock in a transaction dated Thursday, June 6th. The stock was purchased at an average price of $29.87 per share, for a total transaction of $377,586.67. The disclosure for this purchase can be found here. Insiders own 4.33% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in Xencor by 5.2% during the 2nd quarter. BlackRock Inc. now owns 4,324,181 shares of the biopharmaceutical company’s stock valued at $176,988,000 after purchasing an additional 213,329 shares during the period. EcoR1 Capital LLC lifted its position in Xencor by 13.5% during the 2nd quarter. EcoR1 Capital LLC now owns 2,336,557 shares of the biopharmaceutical company’s stock valued at $95,635,000 after purchasing an additional 277,128 shares during the period. Norges Bank acquired a new position in Xencor during the 4th quarter valued at about $28,271,000. Northern Trust Corp lifted its position in Xencor by 1.0% during the 2nd quarter. Northern Trust Corp now owns 611,797 shares of the biopharmaceutical company’s stock valued at $25,040,000 after purchasing an additional 5,796 shares during the period. Finally, Geode Capital Management LLC lifted its position in Xencor by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 550,642 shares of the biopharmaceutical company’s stock valued at $19,911,000 after purchasing an additional 38,127 shares during the period. Institutional investors own 83.02% of the company’s stock.
NASDAQ:XNCR opened at $36.60 on Friday. Xencor has a 12 month low of $27.75 and a 12 month high of $48.38. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -27.94 and a beta of 1.39. The company has a quick ratio of 8.27, a current ratio of 8.27 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $42.52 and its 200-day moving average is $35.38.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.